Oxford, UK – 15 May 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led viral vector CDMO, today announces the launch of its 4 th generation ...

Genezen reports that the company became the first CDMO to license CSL’s Cytegrity™ cell line production system that was designed for the production of lentiviral vectors (LVVs). “We have significant, ...

Brianna Jayanthi, PhD, is a principal scientist at Asimov, where she has helped lead the development of next-generation cell lines for viral vector manufacturing. Since joining Asimov in 2019, she has ...

Licensing of a proven stable producer system for lentiviral vector production represents a significant investment in next-generation technology for Genezen, offering its clients immediate access to ...